The stock's fall snapped a four-day winning streak.
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor ...
Hosted on MSN1mon
LLY Falls Around 14% in 3 Months: How to Play the StockLLY’s price drop in the past three months ... AMGN and VKTX’s products can pose strong competition to Mounjaro/Zepbound and NVO’s Ozempic/Wegovy in the future. Lilly’s stock has risen ...
Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...
Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback